Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported that it has been notified by its third party manufacturing vendor that the manufacturing line related to Rhopressa in …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the appointment of Judith J. Robertson as Chief Commercial Officer, reporting to Thomas Mitro, Aerie President and Chief …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the completion of patient enrollment in the Company’s second Phase 3 registration trial (“Mercury 2”) of Roclatan (netarsudil/latanoprost …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported the successful 90-day topline efficacy results of its Rocket 4 Phase 3 clinical trial of product candidate RhopressaTM, a …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares jumped over 50%, after the glaucoma drug company announced positive top-line efficacy results from its Phase III “Mercury 1” …
Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) pipeline drug Roclatan, a novel once-daily, quadruple-action eye drop being tested for its ability to lower intraocular pressure (IOP) …
Biotech stocks are looking to erase their losses over the past month today, as the iShares Nasdaq Biotechnology ETF (IBB) gained nearly 2%. Among the equities in …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on March …
